Bispecifics Network

Explore Expert Education & Submit Your Questions

Browse curated content by category, watch featured videos, and submit questions as you learn.

Featured Content

CAR T-cell therapy | Image: AdobeStock
Other

Emerging Threats to Cell and Gene Therapy Access

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

View Content
Lungs | Image: AdobeStock
Other

Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC

Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.

View Content
Salman Fazal, MD
Other

Community Bispecific Delivery Requires Operational Readiness, Safety

Establishing baseline oxygen and cognitive assessments helps community teams safely treat older, higher-risk patients, says Salman Fazal, MD.

View Content

Browse by Category

Content Library

OtherArticles

Emerging Threats to Cell and Gene Therapy Access

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

Open
OtherArticles

Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC

Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.

Open
OtherVideo

Community Bispecific Delivery Requires Operational Readiness, Safety

Establishing baseline oxygen and cognitive assessments helps community teams safely treat older, higher-risk patients, says Salman Fazal, MD.

Open
OtherArticles

Pharmacy Leaders Map Path for Outpatient Bispecifics, CAR T

Pharmacy leaders from academic and community practices discuss the infrastructure, partnerships, and payer strategies for outpatient access.

Open
OtherArticles

Straight Talk From a Caregiver: Without Us, Cures Don't Reach Patients

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

Open
Practice ModelsArticles

Bispecific Program Design Varies by Practice Size, Experts Say

Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.

Open
Program ReadinessArticles

Pharmacists Take On Education and Toxicity Triage in Bispecific Care

Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.

Open
Safety & ToxicityArticles

Mirabegron Not Tied to Higher Obesity-Related Neoplasm Risk in OAB

Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.

Open
OtherArticles

NCCN Issues First Guidelines for Patients Devoted to Cancer Caregivers

The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”

Open
OtherArticles

In Chicago, Academic Centers Weigh What It Will Take to Hand Off Bispecifics to the Community

Clinicians from University of Chicago Medicine, Northwestern Medicine, and Loyola Medicine said bispecific antibodies for early-relapse myeloma can be given safely outside the hospital, but staffing, after-hours triage, and community confidence have yet to catch up.

Open
OtherArticles

In Dallas, Community Pharmacy Is Ready for Bispecifics in Myeloma, Hospitals and Prescribers Are Still Catching Up

Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.

Open
OtherArticles

Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.

Open
OtherArticles

Philadelphia Experts Share How Bispecific Delivery in Myeloma Varies by Site

In an AJMC stakeholder interchange, moderator Sandra Susanibar-Adaniya, MD, MS, of Penn Medicine, led academic and community clinicians through the operational, safety, and reimbursement challenges of moving teclistamab-and talquetamab-based regimens into earlier lines of relapsed/refractory multiple myeloma and into outpatient, community-based care.

Open
Access & BillingArticles

91% of Community Oncology Sites Offer Bispecifics Despite Barriers

Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.

Open
OtherVideo

Building Community Infrastructure for Bispecifics and CAR T

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Open
OtherArticles

Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.

Open
OtherVideo

Expanding Access to CAR T-Cell Therapy, Bispecific Antibodies: Swarup Kumar, MD

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Open
Program ReadinessArticles

Advance Planning Eases Bispecific Therapy Burden for Patients

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Open
Program ReadinessArticles

Before the First Bispecific Dose, Community Practices Need a Playbook

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

Open
Practice ModelsArticles

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

Open
OtherArticles

Infrastructure, Payment Gaps Persist for Bispecifics in the Community

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Open
OtherArticles

Bispecifics in the Community: Infrastructure, Education, the Future

Open
OtherVideo

Community Bispecifics Success Hinges on Education, Reimbursement

Community oncology can navigate bispecific therapy rollout with staff training, clear handoffs, and reliable reimbursement, said Lekan Ajayi, PharmD.

Open
OtherVideo

Bispecifics' Step-Up Dosing Puts Pressure on Community Resources

Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.

Open

Have a Question?

Submit a question based on the content you're exploring.